NYSE:ANVS Annovis Bio (ANVS) Stock Price, News & Analysis → A new way to collect income from stocks (From DTI) (Ad) Free ANVS Stock Alerts $13.03 +0.29 (+2.28%) (As of 10:24 AM ET) Add Compare Share Share Today's Range$12.55▼$13.2950-Day Range$8.47▼$12.7652-Week Range$5.42▼$22.49Volume54,528 shsAverage Volume265,410 shsMarket Capitalization$143.46 millionP/E RatioN/ADividend YieldN/APrice Target$27.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Annovis Bio alerts: Email Address Annovis Bio MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside117.5% Upside$27.75 Price TargetShort InterestBearish13.62% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.35) to ($2.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.62 out of 5 starsMedical Sector747th out of 907 stocksPharmaceutical Preparations Industry347th out of 422 stocks 3.4 Analyst's Opinion Consensus RatingAnnovis Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAnnovis Bio has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.62% of the outstanding shares of Annovis Bio have been sold short.Short Interest Ratio / Days to CoverAnnovis Bio has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Annovis Bio has recently increased by 11.11%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAnnovis Bio does not currently pay a dividend.Dividend GrowthAnnovis Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ANVS. Previous Next 2.8 News and Social Media Coverage News SentimentAnnovis Bio has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.Search InterestOnly 18 people have searched for ANVS on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.MarketBeat Follows12 people have added Annovis Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 71% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Annovis Bio insiders have not sold or bought any company stock.Percentage Held by Insiders38.30% of the stock of Annovis Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.83% of the stock of Annovis Bio is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Annovis Bio are expected to grow in the coming year, from ($3.35) to ($2.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Annovis Bio is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Annovis Bio is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report About Annovis Bio Stock (NYSE:ANVS)Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.Read More ANVS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANVS Stock News HeadlinesApril 17, 2024 | finance.yahoo.comIntra-Cellular (ITCI) Up as Depression Drug Meets Study GoalsApril 17, 2024 | americanbankingnews.comAnnovis Bio Sees Unusually High Options Volume (NYSE:ANVS)April 25, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 15, 2024 | americanbankingnews.comAnnovis Bio, Inc. (NYSE:ANVS) Sees Significant Growth in Short InterestApril 4, 2024 | msn.comAnnovis Bio Makes Strides in Neurodegenerative Disease Treatment: 2023 Q4 Results Below Projections, Progress Seen in Clinical TrialsApril 3, 2024 | msn.comAnnovis Bio's Buntanetap Shows Promise in Early Alzheimer’s Disease StudyApril 2, 2024 | markets.businessinsider.comBuy Rating Reiterated for Annovis Bio Amid Anticipated Positive Trial Results for Alzheimer’s and Parkinson’s TreatmentsApril 2, 2024 | investorplace.comANVS Stock Earnings: Annovis Bio Misses EPS for Q4 2023April 25, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 2, 2024 | globenewswire.comAnnovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial ResultsApril 1, 2024 | globenewswire.comAnnovis Announces Publication That Supports Understanding of Buntanetap's Mechanism of Action in HumansMarch 24, 2024 | msn.comAnnovis Bio Nears Milestone in Alzheimer’s Treatment Study with Completion of Data CleaningMarch 21, 2024 | marketwatch.comAnnovis Bio Shares Up 31% on Progress Toward Reporting Data From Alzheimer's StudyMarch 20, 2024 | marketwatch.comAnnovis Bio Completes Data Cleaning for Buntanetap StudyMarch 20, 2024 | finance.yahoo.comANVS Jul 2024 30.000 callMarch 20, 2024 | msn.comAnnovis to release efficacy data on Alzheimer's drug in AprilMarch 20, 2024 | globenewswire.comAnnovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer's DiseaseMarch 18, 2024 | finance.yahoo.comANVS Oct 2024 5.000 putMarch 18, 2024 | finance.yahoo.comANVS Apr 2024 20.000 callMarch 18, 2024 | msn.comAre Options Traders Betting on a Big Move in Annovis Bio (ANVS) Stock?March 15, 2024 | 247wallst.com$10 Biotech Stock Wall Street Says Will Be Up Over 200% This YearMarch 6, 2024 | investorplace.comSell Signal: 3 Stocks to Unload Before the Bubble BurstsMarch 4, 2024 | msn.comAnnovis Bio to Shed Light on Neurodegenerative Diseases at International ConferenceFebruary 29, 2024 | stockhouse.comAnnovis Bio Announces Participation in Forum Discussion at AD/PD(TM) 2024February 28, 2024 | msn.comBrookline Capital Downgrades Annovis Bio (ANVS)February 28, 2024 | markets.businessinsider.comMaintaining Hold on Annovis Bio Amid Phase 3 Parkinson’s Trial Concerns and Financial UncertaintiesFebruary 28, 2024 | msn.comAnnovis Bio falls after Brookline Capital downgrades on PD trial complicationsSee More Headlines Receive ANVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Annovis Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/29/2024Today4/24/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:ANVS CUSIPN/A CIK1477845 Webwww.annovisbio.com Phone610-727-3913FaxN/AEmployees6Year FoundedN/APrice Target and Rating Average Stock Price Target$27.75 High Stock Price Target$36.00 Low Stock Price Target$9.00 Potential Upside/Downside+117.5%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($6.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-56,200,000.00 Net MarginsN/A Pretax Margin-74,496.43% Return on Equity-446.06% Return on Assets-257.97% Debt Debt-to-Equity RatioN/A Current Ratio2.39 Quick Ratio2.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.73) per share Price / Book-17.48Miscellaneous Outstanding Shares11,010,000Free Float6,794,000Market Cap$140.49 million OptionableOptionable Beta1.59 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Maria L. Maccecchini Ph.D. (Age 73)Founder, CEO, President & Executive Director Comp: $965.6kMr. Henry Hagopian III (Age 56)M.B.A., Chief Financial Officer Comp: $510.05kDr. Cheng Fang Ph.D.Senior Vice President of Research & DevelopmentMs. Eve M. Damiano M.S.RAC, Senior Vice President of Regulatory OperationsMs. Melissa GainesSenior Vice President of Clinical OperationsKey CompetitorsVistagen TherapeuticsNASDAQ:VTGNAmylyx PharmaceuticalsNASDAQ:AMLXSagimet BiosciencesNASDAQ:SGMTKaryopharm TherapeuticsNASDAQ:KPTISyros PharmaceuticalsNASDAQ:SYRSView All CompetitorsInstitutional OwnershipWealthspire Advisors LLCBought 990 shares on 2/7/2024Ownership: 0.104%Merit Financial Group LLCSold 19,000 shares on 2/6/2024Ownership: 0.210%Greenwich Wealth Management LLCBought 10,275 shares on 2/1/2024Ownership: 0.100%View All Institutional Transactions ANVS Stock Analysis - Frequently Asked Questions Should I buy or sell Annovis Bio stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Annovis Bio in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ANVS shares. View ANVS analyst ratings or view top-rated stocks. What is Annovis Bio's stock price target for 2024? 4 Wall Street research analysts have issued twelve-month price targets for Annovis Bio's stock. Their ANVS share price targets range from $9.00 to $36.00. On average, they anticipate the company's share price to reach $27.75 in the next year. This suggests a possible upside of 117.5% from the stock's current price. View analysts price targets for ANVS or view top-rated stocks among Wall Street analysts. How have ANVS shares performed in 2024? Annovis Bio's stock was trading at $18.70 at the beginning of 2024. Since then, ANVS stock has decreased by 31.8% and is now trading at $12.76. View the best growth stocks for 2024 here. Are investors shorting Annovis Bio? Annovis Bio saw a increase in short interest in March. As of March 31st, there was short interest totaling 1,500,000 shares, an increase of 11.1% from the March 15th total of 1,350,000 shares. Based on an average trading volume of 268,500 shares, the days-to-cover ratio is currently 5.6 days. View Annovis Bio's Short Interest. When is Annovis Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ANVS earnings forecast. How were Annovis Bio's earnings last quarter? Annovis Bio, Inc. (NYSE:ANVS) released its quarterly earnings results on Friday, March, 29th. The company reported ($1.09) EPS for the quarter. What other stocks do shareholders of Annovis Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Annovis Bio investors own include ADMA Biologics (ADMA), Bionano Genomics (BNGO), KushCo (KSHB), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Auxly Cannabis Group (CBWTF), Novan (NOVN), Sorrento Therapeutics (SRNE), CNBX Pharmaceuticals (CNBX) and Enerplus (ERF). When did Annovis Bio IPO? Annovis Bio (ANVS) raised $10 million in an initial public offering (IPO) on Wednesday, January 29th 2020. The company issued 1,400,000 shares at $6.00-$8.00 per share. ThinkEquity (a division of Fordham Financial Management, Inc. ) acted as the underwriter for the IPO. How do I buy shares of Annovis Bio? Shares of ANVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:ANVS) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican AlternativeBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldPrepare for a recession unlike any otherAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annovis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
